{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-276225","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.046073+00:00","generated_at":"2026-06-08T05:29:53.191586+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ProKidney reports positive Phase 2 data for REACT; narrows Phase 3 enrollment; appoints new CEO","bullets":["Positive interim Phase 2 data: REACT preserved kidney function up to 30 months in high-risk Stage 3b/4 diabetic CKD patients.","Phase 3 proact 1 protocol modified: eGFR range narrowed to 20-35 ml/min/1.73m2; enrollment paused until H1 2024.","Manufacturing paused due to QP audit documentation deficiencies; no safety issues; expected to resume H1 2024.","Bruce Culleton appointed CEO effective Nov 15, 2023; Tim Bertram transitions to scientific advisory role.","Cash and marketable securities $396M as of Sept 30, 2023; funding into Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-276225","json":"https://secwatch.observer/filing/0001193125-23-276225.json","markdown":"https://secwatch.observer/filing/0001193125-23-276225.md","text":"https://secwatch.observer/filing/0001193125-23-276225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/d83356d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:29:53.191586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06ad5b35da","claim":"Bruce Culleton was appointed as Class III Director at PROKIDNEY CORP..","evidence_excerpt":"the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"1842eb883d","claim":"Tim Bertram departed as Director at PROKIDNEY CORP..","evidence_excerpt":"Dr. Bertram will resign from the Board of Directors (the “Board”) of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ce9ca34f8b","claim":"Bruce Culleton was appointed as Chief Executive Officer at PROKIDNEY CORP..","evidence_excerpt":"the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ea5dd54e59","claim":"Tim Bertram departed as Chief Executive Officer at PROKIDNEY CORP..","evidence_excerpt":"the board of directors (the “Board”) of ProKidney Corp. (the “Company”) approved the termination, without cause, of Tim Bertram, Ph.D., Chief Executive Officer of the Company, effective November 15, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}